Fig. 2From: Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitisAnalysis of time after administration of mepolizumab to onset of effect. After administering mepolizumab, we confirmed some clinical benefit in all 43 patients. We found clinical efficacy of mepolizumab 3.4 ± 3.0 months after administration (mean ± SD); for 15 patients (34.9%), efficacy was observed within 1 monthBack to article page